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ABSTRACT
Transcription co-activators CBP and p300 are re-
cruited by sequence-specific transcription factors
to specific genomic loci to control gene expression.
A highly conserved domain in CBP/p300, the TAZ2
domain, mediates direct interaction with a variety
of transcription factors including the myocyte
enhancer factor 2 (MEF2). Here we report the
crystal structure of a ternary complex of the p300
TAZ2 domain bound to MEF2 on DNA at 2.2A ˚ reso-
lution. The structure reveals three MEF2:DNA
complexes binding to different sites of the TAZ2
domain. Using structure-guided mutations and a
mammalian two-hybrid assay, we show that all
three interfaces contribute to the binding of MEF2
to p300, suggesting that p300 may use one of the
three interfaces to interact with MEF2 in different
cellular contexts and that one p300 can bind three
MEF2:DNA complexes simultaneously. These
studies, together with previously characterized
TAZ2 complexes bound to different transcription
factors, demonstrate the potency and versatility of
TAZ2 in protein–protein interactions. Our results
also support a model wherein p300 promotes the
assembly of a higher-order enhanceosome by sim-
ultaneous interactions with multiple DNA-bound
transcription factors.
INTRODUCTION
CBP and p300 are transcription co-activators of diverse
gene expression programs (1). Their essential roles have
been demonstrated by genetic studies and diseases
associated with mutations in CBP/p300. Mice deﬁcient
in p300 lack cardiomyocyte proliferation and muscle-
speciﬁc gene expression (2), whereas elevated p300 levels
lead to myocardial hypertrophy (3). Mutations in CBP
cause Rubinstein–Taybi Syndrome, a neurological
disorder characterized by severe mental retardation (4).
Disruptions of CBP and p300 regulation and function
have also been linked to numerous cancers (5). CBP/
p300 enhances transcription by facilitating the assembly
of activating transcription complexes at the promoter and
by modifying chromatin structure through its histone
acetyltransferase (HAT) activity that can also modify
non-histone proteins. These large nuclear proteins do
not bind DNA but contain multiple domains capable of
interacting with a variety of transcription factors (6),
including the KIX domain that binds CREB and a
number of cysteine–histidine rich regions (CH1–3), each
of which binds directly to a large number of proteins (7).
The CH3 region, which contains the TAZ2 domain, has
been shown to interact with more than 20 proteins
including viral protein E1A and host transcription factor
p53 (8–18). Thus, CBP/p300 is extremely versatile in
engaging numerous transcription factors to regulate gene
expression (19–21). However, the molecular basis for this
remarkable versatility is not well understood.
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transcription factor partner of CBP/p300 in muscle,
neurons and T cells (22–26). MEF2 is a class of transcrip-
tion factors highly conserved in eukaryotes (27,28). Earlier
genetic studies have demonstrated a central role of MEF2
in myogenesis (29–32). It is now clear that the MEF2
proteins (MEF2A-D) have broad roles in the differenti-
ation, proliferation, and survival/apoptosis of a wide
range of cell types (28,33,34). MEF2 also serves as a key
regulator of stress responses and adaptive programs in
animals, including ﬁber-type switch of skeletal muscle,
hypertrophic growth of heart and activity-dependent re-
modeling of neuronal circuitry (35–39).
MEF2 turns on and off gene expression in a
calcium-dependent manner (40). In the resting state,
MEF2 recruits co-repressors such as Cabin1/Cain and
histone deacetylases (HDAC) to speciﬁc loci of the
genome to inhibit the expression of target genes (41–48).
Upon activation, the co-repressors dissociate from MEF2
via calcium-dependent mechanisms (33,40,49–52); the
DNA-bound MEF2 subsequently interacts with other
calcium-activated transcription factors (e.g. NFAT and
CREB) and recruits co-activators such as CBP/p300 and
myocardin to activate transcription (1,2,22–26,53,54). The
HDACs and CBP/p300 also regulate the transcriptional
activity of MEF2 directly by controlling the acetylation
state of speciﬁc lysine residues of MEF2 (55,56). The
overall transcription state of MEF2-bound promoters is
tightly controlled by signal-dependent protein–protein
interactions between MEF2 and different co-regulators.
Establishing how MEF2 interacts with these co-regulators
will be a key to understanding the mechanisms of
MEF2-regulated transcription.
The MEF2 family of transcription factors shares a
highly conserved domain at the N-terminus, known as
the MADS-box/MEF2 domain that mediates DNA
binding, dimerization and protein–protein interactions
with a variety of protein partners, including transcription-
al co-repressors. Systematic structural studies reveal that a
short amphipathic helix conserved in Cabin1 and class IIa
HDACs (HDAC4, 5, 7 and 9) (referred to as
MEF2-binding motif hereafter) binds a hydrophobic
groove of MEF2 (53,57,58). These studies established a
structural model for co-repressors to bind to MEF2
through their core interaction domains. Here, we
characterized the interactions between MEF2 and its
co-activator p300 by structural and biochemical
analyses. These studies reveal the ﬁrst atomic model of
sequence-speciﬁc recruitment of transcription co-activator
p300 by a DNA-bound transcription factor and provide
new insights into the p300-mediated enhanceosome
assembly.
MATERIALS AND METHODS
Materials
DNA plasmids of human MEF2A, Gal4-luciferase
reporter, Gal4-MEF2D were kindly provided by Dr
Xiangjiao Yang (McGill University). pET28a, pET30b
and Rosetta BL21(DE3) pLysS competent cells were
purchased from Novagen. Primers (for cloning) and
oligo (for crystallization) were ordered from Integrated
DNA Technologies (IDT). Glutathione-Sepharose beads,
Sp sepharose, MonoS and Superdex 200HR were
purchased from GE healthcare. In vitro transcription/
translation kit was purchased from Promega and
35S-Met was from Pierce. The mutations were generated
using Quickchange mutagenesis kit (Stratagene).
Lipofectamine 2000 was purchased from Invitrogen.
Dual-luciferase reporter assay kit was from Promega.
HeLa cells (ATCC) were grown in DMEM containing
10% fetal bovine serum. Other chemicals and reagents
were purchased from Sigma.
Protein expression and puriﬁcation
Human MEF2A (1–95) was expressed and puriﬁed as
described previously (53). Brieﬂy, pET30b-MEF2A
(1–95) was transferred into BL21(DE3) pLysS Rosetta
cells. The cells were induced at room temperature for
5h. The induced cells were lysed by sonication in the
lysis buffer (50mM HEPES, pH 7.6, 300mM NaCl,
1mM EDTA, 1mM DTT, 10% glycerol, protease inhibi-
tors cocktails). The lysate was cleared by high-speed cen-
trifugation and applied to Sp Sepherase column. Fractions
containing MEF2 were pooled and further puriﬁed by
superdex 200HR column using the buffer (10mM
HEPES, pH 7.6, 250mM NaCl, 1mM EDTA, 1mM
DTT).
The TAZ2 domain of human p300 (1726–1837) was
cloned into pET28a. Based on the NMR structure of the
CBP TAZ2 domain (59), the four cysteines (Cys1738,
1746, 1789 and 1790) not involved in zinc coordination
were mutated to serine for better stability. The construct
was transferred into Rosetta BL21(DE3) pLysS and
induced at room temperature for 5h with additional
150mM ZnSO4 in the medium. The cells were lysed by
sonication. The p300 TAZ2 domain was ﬁrst puriﬁed by
Ni-NTA Agarose (QIAGEN) and eluted in 15mM
HEPES7.6, 1M NaCl, 15mM b-mercaptoethanol and
100mM Imidazole. The imidazole was removed by
dialysis and His-tag was cleaved off by thrombin. The
p300 domain was further puriﬁed by MonoS, followed
by superdex 200 HR in the running buffer of 10mM
HEPES pH 7.6, 25mM NaCl, 0.4M NH4OAc, 2mM
DTT and 10mM ZnSO4.
Crystallization
The complex was prepared by mixing puriﬁed DNA,
MEF2 dimer and the p300 TAZ2 domain in the
superdex 200 HR running buffer (see above). The initial
stoichiometry was 1:1:1 but after several rounds of opti-
mization with various crystallization conditions and molar
ratios of the complex composition, the best crystals came
from complexes prepared by mixing 0.15mM double
stranded DNA, 0.3mM MEF2 dimer and 0.9mM p300
TAZ2 domain. The complex crystals were grown by the
hanging drop method against a reservoir solution of
50mM BTP pH 6.3, PEG 1K 16% and 2mM DTT
at 17C.
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The crystals were transferred into the cryo-buffer of 32%
PEG 1K and 50mM BTP pH 6.3 and ﬂash frozen in liquid
nitrogen. The data were collected in Advanced Light
Source (ALS 8.2.1, Berkeley). Data were processed by
HKL2000 (60). The p300:MEF2:DNA complex structure
was solved by the molecular replacement method using the
MEF2A:DNA crystal structure as a partial search model
in Phaser (61,62). The initial search by molecular replace-
ment located three MEF2:DNA complexes in the asym-
metric unit. Electron density calculated using phases
generated from the partial model revealed clearly
the position of the p300 TAZ2 domain. Model building
was carried out in O and Coot (63,64). The reﬁnement
was carried out using CNS (65,66) and the model was
analyzed using programs from CCP4 (67). The
Ramachadran plot of the ﬁnal model has 96.7%
of residues in the favorite region and 3.3% of residues
in the allowed region and no residue in the dis-
allowed region. All ﬁgures were prepared in Pymol
(The Pymol Molecular Graphics System, DeLano
Scientiﬁc LLC).
GST-pulldown
The TAZ2 fragments were expressed as GST fusion
proteins. The proteins were puriﬁed by GST afﬁnity
column and gel ﬁltration in the S200 buffer (50mM
HEPES, pH 7.6, 300mM NaCl, 1mM DTT, 10%
glycerol and protease inhibitor cocktail). The quality
and concentration of the proteins were checked by
SDS–PAGE. The full-length MEF2A was prepared
using an in vitro translation kit and labeled with
35S-MET. The mixtures of labeled MEF2A and
puriﬁed GST-p300 fusion proteins were incubated with
GST beads for 1h at 4C, followed by three times
wash using the same S200 buffer. The beads were
collected for SDS–PAGE analysis followed by exposure
to X-ray ﬁlm.
Luciferase reporter assay
A plasmid was constructed to express the p300 TAZ2
domain (1721–1837) fused to the N terminal end of
VP16 (Figure 5A). MEF2-Gal4 and Gal4 reporter
plasmids were described by Gregoire and Yang (68). All
these expression constructs were co-transfected to HeLa
cells using lipofectamine 2000 or calcium phosphate. The
experiments were performed in triplicate, and luciferases
were measured using the dual-luciferase reporter assay kit
according to manufacturer’s instructions. Brieﬂy, 20mlo f
cell lysate was transferred to a luminometer tube
predispensed with 100ml of Luciferase Assay Reagent II
(LARII), and luminescence of ﬁreﬂy luciferase was
measured by a Luminometer (Berthold). Then, 100mlo f
Stop & Glo Reagent was added to the same tube and the
light emission of renilla luciferase was recorded. Results
are presented as activity ratios of ﬁreﬂy over renilla
luciferases.
RESULTS
p300 TAZ2 domain binds the MADS-box/MEF2 domain
The interaction between MEF2 and p300 was analyzed
previously by several reports (25,26,69). These studies
revealed that the MADS-box/MEF2 domain of MEF2
(amino acids 1–95) and a C-terminal region of p300
(amino acids 1572–1868) were necessary and sufﬁcient to
mediate p300 and MEF2 interaction. We conﬁrmed this
result by GST pull-down assay using individually puriﬁed
proteins. By deletion analyses, we narrowed down the
MEF2-binding region in p300 to a fragment that
encompasses residues 1721–1837 (Figure 1, lane 4). This
fragment corresponds to the TAZ2 domain of the CH3
region (amino acids 1725–1812) and a C-terminal exten-
sion (amino acids 1813–1837) with unknown function. We
will refer this fragment (amino acids 1721–1837) as the
TAZ2 domain hereafter. We previously hypothesized
that the C-terminal extension might bind MEF2 analo-
gously to class IIa HDACs and Cabin1 (58). However,
further deletion studies revealed that while p300
(1805–1837) did bind MEF2 (Figure 1, lane 5), its
afﬁnity for MEF2 appeared to be much lower than that
of p300 (1721–1837) (Figure 1, lanes 4 and 5). Moreover,
the core TAZ2 domain of p300 (1721–1812) retained
partial binding activity for MEF2 (Figure 1, lane 6). We
also analyzed the interaction between p300 (1721–1837)
and MEF2A (1–95) using electrophoresis mobility shift
assay (EMSA), surface plasmon resonance (SPR),
multi-angle light scattering (MALS), mass spectrometry
and ﬂuorescence anisotropy. While these experiments con-
ﬁrmed the binding of p300 (1721–1837) and MEF2A
(1–95) in solution, quantitative analysis of binding
constant and stoichiometry was complicated by the fact
that the complex appears to be in equilibrium between
several species (data not shown). Moreover, the p300
TAZ2 domain alone showed high background binding
to DNA, making the full titration of the MEF2:DNA
complex by high concentration of TAZ2 difﬁcult.
Figure 1. In vitro binding assay of the interaction between the p300
TAZ2 domain and MEF2A. Top panel: binding of the
35S-labeled
MEF2A to various GST-TAZ2 fusion proteins. Lane 2 was MEF2A
with beads only. Lane 3 was GST only protein. Bottom panel:
GST-TAZ2 fusion proteins used in the top panel were analyzed by
SDS–PAGE. The non-degraded fusion protein bands are indicated by
stars.
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binds MEF2 signiﬁcantly differently from Cabin1 and
class IIa HDACs in that p300 uses a larger domain
instead of a short helix.
Crystallographic analysis of the p300:MEF2:DNA
complex
In order to analyze the details of p300:MEF2 interaction,
we crystallized a complex between p300 (1726–1837) and
MEF2A (1–95) on DNA. Our initial crystallization was
hindered by the instability of p300 (1726–1837) due to the
large number of cysteine residues in this region. Based on
the NMR structure of the CBP TAZ2 domain (59), we
mutated four cysteine residues (Cys1738, 1746, 1789 and
1790) that do not coordinate with zinc to serine. The
cysteine-mutated p300 TAZ2 domain showed much
improved stability and retained the same ability to bind
MEF2 as the wild-type protein (data not shown). Using
this engineered p300 (1726–1837) together with MEF2A
(1–95) and a double stranded oligonucleotide containing
the consensus MEF2 binding element (see Figure 2A
below), we successfully crystallized the p300:MEF2:
DNA complex. The crystals diffracted to 2.2A ˚ . The
statistics of data collection and structure reﬁnement are
summarized in Table 1.
Overall structure of the p300:MEF2:DNA complex
The overall shape of the complex resembles a trefoil with
the p300 TAZ2 domain in the center and the MEF2
dimer:DNA complexes at the leaf positions (Figure 2A).
The core of the p300:MEF2:DNA complex is assembled
through extensive helical packing that involves a total of
10 helices from the TAZ2 domain and the MADS-box/
MEF2 domain (Supplementary Figure S1). The three
MEF2 dimer:DNA complexes bind the p300 TAZ2
domain via three distinct and non-overlapping interfaces:
Interface I (IF-I), Interface II (IF-II) and Interface III
(IF-III), respectively (Figure 2B). The buried solvent ac-
cessible surface areas for these interfaces are:
IF-I=1213.8A
2, IF-II=1223.1A
2 and IF-III=
1117.0A
2. The p300 TAZ2 domain in the complex is
composed of four helices, a1 (amino acids 1727–1746),
a2 (amino acids 1758–1766), a3 (amino acids 1782–1793)
and a4 (amino acids 1806–1833) that pack against each
other (Figure 2C). The structure is further stabilized by
three zinc ions that are chelated between a1–a2 (Finger 1),
Figure 2. Structure of the p300 TAZ2 domain bound to MEF2 on DNA. (A) Overall structure in ribbon style. The MEF2 dimers are colored in
yellow, magenta and blue, respectively; p300 is in green; the DNA backbone is shown in gold and its sequence is listed below. The secondary
structural elements of one MEF2 dimer are labeled. (B) Protein binding interfaces: the proteins in the complex are shown in surface model and
colored as in A. The three protein–protein interaction interfaces are labeled as IF-I, IF-II and IF-III. (C) Zoom-in view of the p300 TAZ2 domain.
The four helices (a1–a4) and three zinc ﬁngers (red spheres) are indicated. Part of the second zinc binding loop is disordered and labeled in a dashed
line. (D) Superposition of the p300 TAZ2 domain in the MEF2-bound complex (green) with the unbound form (blue, 3IO2) (70).
Nucleic Acids Research, 2011,Vol.39, No. 10 4467a2–a3 (Finger 2) and a3–a4 (Finger 3), respectively. Part
of the second ﬁnger (amino acids 1772–1778) is disordered
in the crystal and labeled in a dash line. Each zinc ion is
bound by one histidine and three cysteines in an
HCCC-type coordination.
The MADS-box/MEF2 domain in the complex forms
an intertwined dimer; each monomer consists of helix H1
(amino acids 15–37), b strand S1 (amino acids 41–49), b
strand S2 (amino acids 53–59), helix H2 (amino acids
62–70), b strand S3 (amino acids 76–80) and helix H3
(amino acids 82–90) (Figure 2A). For each MEF2 dimer,
helix H1 and the N-terminal tail form the major
DNA-binding surface that binds the double stranded
DNA at the periphery of the complex, while the pair of
H2 helices form the protein-binding interface with the
TAZ2 domain in the center of the complex. All three
MEF2 dimers show fully folded MADS-box/MEF2
domain (Figure 2A). The three MEF2A dimer:DNA
complexes bound to the TAZ2 domain are nearly iden-
tical to each other and highly similar to the ‘apo’
MEF2A:DNA complex (Supplementary Figure S2).
There is no interaction between the individual MEF2
dimer:DNA complexes.
Rigid p300 TAZ2 domain
Our TAZ2 structure reveals a protein fold that is very
similar to the homologous TAZ2 domain of CBP ﬁrst
solved by NMR (59). The crystal structure of the
unbound p300 TAZ2 domain has recently been reported
(70). Superposition of the p300 TAZ2 domain in the
unbound state with that in the MEF2-bound complex
shows that the two structures are very similar, although
the N-terminal end of a1 and the C-terminal end of a4
have slightly different trajectories (Figure 2D). The a2-a3
loop also displays signiﬁcant differences due to different
crystal packing interactions. The spatial arrangement of
the four helices and the structure of the three zinc binding
sites are highly conserved in the unbound state and in
complexes with different protein partners, although the
loops between the helices show a certain degree of vari-
ability due to different crystal packing and protein–
protein interactions (9,14,16,59). A signiﬁcant difference
from the solution structure of the TAZ2 domain is that we
observed an extended helix a4 in the crystal structure of
the p300 TAZ2 domain (Figure 2C). This long helix a4
was also observed in a ligand-free TAZ2 structure (70).
Overall, the structural comparisons suggest that the for-
mation of the p300:MEF2:DNA complex involves largely
rigid body docking interactions of the preformed
MEF2A:DNA complex and the p300 TAZ2 domain.
Protein–protein interactions at Interface I
Interface I is formed between helix a4 of the TAZ2
domain and one of the MEF2 dimers. Here helix a4o f
the TAZ2 domain packs diagonally between helices H2 of
the MEF2 dimer. This arrangement is very similar to the
binding of the amphipathic helix of Cabin1 and HDAC9
to MEF2, however, the exact positions of the helices are
slightly different in different complexes (Figure 3A).
Previously we showed that the binding of Cabin1 and
HDAC9 to MEF2 induced a shift of helix H2 and con-
formational changes of the L2 loop between helix H2 and
strand S3 (53,57,58). The L2 conformations of MEF2
bound to the p300 TAZ2 domain are indeed notably dif-
ferent from that seen in the Cabin1:MEF2 and
HDAC9:MEF2 complexes (Figure 3A). The detailed
interactions of IF-I share many features observed at the
Cabin1:MEF2 and HDAC9:MEF2 interfaces (Figure 3B
and C). Leu1818 and Leu1822 of p300 bind the hydropho-
bic groove of MEF2 similarly to homologous leucine
residues in Cabin1 and HDAC9 (residues of p300 are
italicized throughout the text) (57,58). Surrounding the
hydrophobic interactions are numerous salt bridges and
hydrogen bond networks. At the N-terminal end of TAZ2
a4, Arg1814 engages in electrostatic interactions with
Asp61 and Asp63 of MEF2, whereas Gln1811and
Gln1815 form hydrogen bonds with Asp63 and the main
chain carbonyl of Thr70 of MEF2, respectively. Both
Gln1811and Gln1815 are also in van der Waals contact
with Tyr69 of MEF2. At the C-terminal end of TAZ2
a4, Arg1829 engages in electrostatic interactions with
Asp61 and Asp63 of the other MEF2 monomer. Along
the helix of TAZ2 a4, the long aliphatic side chains of
Arg1814, Gln1815, Gln1819 and Arg1821 make extensive
van der Waals contacts with residues of helix H2 of the
MEF2 dimer. Here, Gln1819 also forms a hydrogen bond
with Thr70 while Arg1821 forms a salt bridge with Glu71.
Table 1. Data collection and reﬁnement statistics
Space group P 21 21 21
Unit cell parameters (A ˚ ) a=74.85A ˚ , b=90.93A ˚ , c=144.8A ˚
Resolution (A ˚ ) 30.0–2.09 (2.16–2.09)
a
Reﬂections (Total/unique) 1317602/59524
I/s(I)
b 27.3 (1.95)
Rsym (%)
c 8.7 (70.9)
Completeness (%) 100 (100)
Reﬁnement
Resolution (A ˚ ) 29.666–2.192 (2.217–2.192)
Reﬂections 49213 (4536)
Completeness (%) 95.698
R (%)
d 22.13 (25.62)
Rfree (%) 27.16 (35.15)
Model quality
RMSD bond length (A ˚ )
e 0.008
RMSD bond angles () 1.400
Overall B-factor (A ˚ 2) 36.0
Number of total atoms
f 7089
Protein atoms 5302
Nucleic acid atoms 1787
Ions 3
H2O 238
aThe data for the highest resolution shell are shown in brackets.
bI/s(I)—ratio of mean intensity to a mean standard deviation of
intensity.
cRsym=|I<I>|/I, where I is the observed intensity, <I> is the
statistically weighted average intensity of multiple observations of
symmetry-related reﬂections.
dRfactor=||Fo||Fc||/|Fo|, where Fo and Fc are observed and
calculated structure factor amplitudes, respectively. Rfree is calculated
for a randomly chosen 10% of reﬂections.
eRMSD—root mean square deviation
fNumber of protein atoms and nucleic acid atoms—the ordered region.
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Cabin1 and HDAC9 as well as new features of protein–
protein interactions.
Protein–protein interactions at Interface II
Interface II is formed between helix a1 and the ﬁrst zinc
loop of the TAZ2 domain and a second MEF2 dimer.
Here, helix a1 of the TAZ2 domain lies above the two
H2 helices of the MEF2 dimer at a cross angle of 60
(Supplementary Figure S3). The interface is composed of
two separated foci of binding interactions; the ﬁrst being
between the N-terminal part of the TAZ2 a1 helix and
helix H2 of one MEF2 monomer (Figure 4A). Met1725
and Leu1733 of p300 and Leu67 of MEF2 form a central
hydrophobic patch that is surrounded by a number of
electrostatic and hydrogen bond interactions, including
salt bridges between Arg1737 and Asp63 and between
Arg1732 and Glu71. At the second binding site of IF-II,
the C-terminal part of TAZ2 a1 helix and part of the ﬁrst
zinc loop interact with helix H2 of the other MEF2
monomer. Leu1755 of p300 and Leu67 of MEF2 form
the hydrophobic core. Leu67 also makes van der Waals
contacts with Gln1740 and His1744, while Glu71 makes
hydrogen bonds with the main chain and side chain of
Ser1757. The side chain of Arg1737 and Pro1756 also
make van der Waals contacts with Thr70 and Glu71,
respectively.
Protein–protein interactions at Interface III
Interface III is formed between helices a1 and a3 of the
TAZ2 domain and a third MEF2 dimer. Here, a1 and a3
of the TAZ2 domain pack against helix H2 of each of the
two MEF2 monomers, both in an approximately parallel
orientation (Supplementary Figure S4). Similar to IF-II,
IF-III is also composed of two separated foci of binding
interactions. One is between helix a1 of the TAZ2 domain
and helix H2 of one of the MEF2 monomers (Figure 4B).
Here, Pro1727, Gly1728, Ser1730 and Arg1731 of p300
and Asp63, Lys64, Leu66, Leu67 and Thr70 of MEF2
engage in a pseudo knobs-into-holes type helix packing
interaction. Arg1731 also forms a hydrogen bond with
Thr70. At the second binding site (Figure 4C), Lys1783,
Gln1784, Ala1787, Cys1790, Tyr1791 and Lys1794 on the
exposed face of p300 a3 form an extensive interface with
Asp61, Asp63, Lys64, Leu67 and Glu71 on helix H2 of
one of the MEF2 monomers. Most notably, Cys1790 and
Tyr1791 of p300 and Leu67 of MEF2 form a hydrophobic
patch, Lys1783 and Lys1794 engage in electrostatic inter-
actions with Asp61 and Glu71, respectively. Overall, the
binding modes of IF-II and IF-III are substantially differ-
ent from that seen in the Cabin1:MEF2 complex and
HDAC9:MEF2 complex, but both interfaces bury large
solvent accessible surface areas and display good shape
and chemical complementarity.
Biochemical analysis of the p300:MEF2 interaction
To test if the protein–protein interfaces seen in the crystal
structure contribute to p300:MEF2 interaction, we
analyzed a series of structure-guided mutations using a
mammalian two-hybrid assay speciﬁcally designed for de-
tecting the interaction between the p300 TAZ2 domain
and the MADS-box/MEF2 domain in mammalian cells.
Initially, we transfected a MEF2-responsive luciferase
reporter with full-length p300 and MEF2 to detect
MEF2-p300 interaction. These studies did not yield inter-
pretable results due to high background, presumably
caused by the endogenous MEF2 and p300. To
overcome this problem, we adopted a mammalian
Figure 3. Protein–protein interactions at Interface I. (A) Structural
comparison of Interface I (p300 in green and MEF2 in gold) with
the Cabin1:MEF2:DNA complex (red) and the HDAC9:MEF2:DNA
complex (cyan). The structures are superimposed by the Ca backbone
of the b strands of the MEF2 core. (B) View from the side of helix a4
of the p300 TAZ2 domain. Interacting residues are shown in stick
model. Throughout the illustrations, residues from p300 are italicized
and labeled with black fonts while residues from MEF2 are labeled
according to the protein color. (C) View from the C-terminal end of
helix a4.
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DNA-binding domain (GAL4-MEF2) and the p300
TAZ2 domain with VP-16 (TAZ2-VP16) (Figure 5A).
This setup allows us to detect the interaction between
TAZ2 and MEF2 with minimal interference from en-
dogenous factors. A potential caveat of this approach is
that MEF2 is not directly bound to DNA whereas under
physiological conditions p300 is recruited by DNA bound
MEF2. However, we have previously shown that free
MEF2 and DNA-bound MEF2 bind co-factors with
similar afﬁnities, suggesting that the structure of MEF2,
at least in the MADS-box/MEF2 domain, is conserved
between the free and DNA-bound forms (57). HeLa
cells co-transfected with constructs of GAL4-MEF2 and
TAZ2-VP16 together with a GAL4-driven reporter
plasmid produced a strong signal comparable to that
generated by the positive control of GAL4-VP16 (data
not shown). At Interface I, the double mutation
Leu1818Ala/Leu1822Ala caused a signiﬁcant reduction
of the luciferase signal, whereas mutation of Gln1815Ala
and Gln1815Tyr had little effect (Figure 5B). These results
suggest that the hydrophobic residues at the center of IF-I
are important for binding, whereas residues at the periph-
ery are more tolerable to mutations. At Interface II,
double mutation Leu1733Arg/Arg1737Ala and triple
mutation Leu1733Ala/Arg1737Ala/Gln1740Ala reduced
the luciferase signal substantially, whereas the single
mutation Gln1740Ala had only partial effect.
Interestingly, the mutation Gln1740Tyr enhanced the
luciferase signal, suggesting that the Tyrosine residue
introduced at position 1740 may interact better with
MEF2, presumably by inserting into the hydrophobic
groove between helices H2. These mutational data are
consistent with the structural features of IF-II and
suggest that IF-II contributes to p300:MEF2 interaction
in solution. At Interface III, mutation Arg1731Ala and
Tyr1791Ala partially reduced the luciferase signal, which
is consistent with the structural roles of these residues at
IF-III. However, the double mutation Arg1731Ala/
Tyr1791Ala enhanced the luciferase signal. The mechan-
ism of this gain-of-function mutation is not clear. It is
possible that the Arg1731Ala/Tyr1791Ala double mutant
adopts a new way to bind MEF2 that is different than seen
in the crystal structure. Taken together, these data suggest
that protein–protein interactions observed at interfaces I,
II and III contribute to the binding of the p300 TAZ2
domain to MEF2 in solution. For some of the mutations
that showed strong effects in the luciferase assay, such as
the double mutant Leu1818Ala/Leu1822Ala and
Leu1733Arg/Arg1737Ala, our GST-pulldown also con-
ﬁrmed that the mutant proteins lost the binding to
MEF2 in vitro (data not shown).
DISCUSSION
The crystal structure of the p300 TAZ2 domain reported
by Miller et al. (59,70) reveals a new feature that is not
seen in the previous NMR structure of the CBP TAZ2
domain, namely an extended helix a4. This unusually
long helix makes no contacts with the rest of the TAZ
domain but engages in extensive interactions with
symmetry related molecules in crystal (70). It was not
observed in the NMR structure of the same domain
bound to p53 because a shorter p300 fragment
(1723–1812) was used (14). However, the extended helix
a4 was involved in extensive crystal packing interactions
in the structure reported by Miller et al. (59,70), a question
remains if the observed structure of helix a4 is a result of
crystal packing. The p300 TAZ2 domain in our crystal
structure reveals a similar extended helix a4, which,
instead of making crystal contacts, engaged in extensive
interactions with a MEF2 dimer at IF-I. This observation
Figure 4. Protein–protein interactions at interfaces II and III. (A) The
interaction network at Interface II. (B) Interactions at Interface III
viewed from the side of helix a1. (C) Interactions at Interface III
viewed from the side of helix a3.
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property of the p300 TAZ2 domain. Consistent with this
view, CD analysis indicated that the C-terminal region of
p300 TAZ2 domain forms alpha helix in solution (15).
Our studies further suggest that a potential function of
this long helix is to mediate protein–protein interactions
with other proteins, including a variety of transcription
factors, such as MEF2.
Based on the crystal structure of the Cabin1:MEF2:
DNA complex and sequence homology, we have previ-
ously hypothesized that the region of p300 corresponding
to residues Leu1807 to Gln1819 could form an amphipath-
ic helix to bind MEF2 in a way similar to Cabin1 (58). Our
structure reveals that this region of p300 indeed forms an
alpha helix as part of a4, but it is packed against helix a3
and sterically blocked from MEF2 binding. Instead,
MEF2 at IF-I binds to a hydrophobic patch on helix a4
that is centered around Leu1818 and Leu1822. This hydro-
phobic patch has been noted in the unbound structure of
the p300 TAZ domain, which mediates the majority of
crystal packing interactions (70). Despite the shift of the
predicted MEF2-binding site, the binding mode between
MEF2 and the TAZ2 domain at IF-I is remarkably similar
to that seen in the Cabin1:MEF2:DNA complex and the
HDAC9:MEF2:DNA complex, whereas those at IF-II
and III are signiﬁcantly different from the canonical
mode deﬁned previously (57).
A frequently observed mode of co-factor recruitment in
transcription complexes is binding-induced folding.
Usually one protein with a stably folded domain
presents a template for the binding and folding of its
partner with intrinsically disordered regions. The TAZ2
domain serves as the binding site for the transcription ac-
tivation domains of a number of transcription factors,
including STAT1 and p53, which are disordered in
solution and adopt a short helix to bind the hydrophobic
surface between helices a1, a2 and a3 (14,16). The
conserved region-1 (CR1) of the adenoviral protein E1A,
which is unstructured in solution, also binds this region in
a helical conformation (9). The binding sites for different
factors on TAZ2 partially overlap, such that E1A can
compete with p53 for p300 binding (9). The hydrophobic
surface between helices a1, a2 and a3 is also a
MEF2-binding site in the p300:MEF2 complex (IF-III).
However, the binding of MEF2 to TAZ2 involves
mostly rigid body docking without signiﬁcant structural
changes of either MEF2 or the TAZ2 domain.
CBP/p300 can acetylate speciﬁc lysine residues in MEF2
to enhance its DNA binding and transcriptional activity
(56,71). The fact that the TAZ2 domain (amino acids
1721–1837) is adjacent to the HAT domain in p300
(amino acids 1066–1707) suggests that p300 could acetyl-
ate MEF2 within the same complex. It should be noted
that the transcription activation domain of MEF2, which
is located beyond the MADS-box/MEF2 domain at the
C-terminal end, might interact with p300 at additional
regions. Thus in the context of full-length proteins, p300
and MEF2 may bind each other through multiple contacts
and a variety of binding modes.
CBP/p300-mediated enhanceosome assembly has long
been hypothesized (19–21). Our structure provides the
ﬁrst example where a p300 domain is directly recruited
to DNA by a DNA-bound, sequence-speciﬁc transcription
factor. A surprising ﬁnding is that MEF2 binds the p300
TAZ2 domain at three distinct and non-overlapping
surfaces, leading to an assembly of a higher-order
enhanceosome structure wherein three DNA-bound
MEF2 dimers are ‘attracted’ to different faces of the
Figure 5. Structure-guided biochemical analyses of p300:MEF2 interactions. (A) Diagram of the biochemical assay. (B) Luciferase reporter assay of
p300 TAZ2 mutants. Columns 1–3 are controls. Column 4 is from wild-type p300 and MEF2 interaction. Columns 5–8 are IF-I mutants, 10–14 are
IF-II mutants and 16–19 are IF-III mutants. Column 6 is a combined mutant of IF-I and IF-II.
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scriptional regulation by p300 and MEF2. First, the
TAZ2 domain from one p300 molecule could interact
with three MEF2 dimers bound to DNA, thereby
promoting the assembly of higher-order structures in the
promoter and long-range interactions of DNA-bound
MEF2 complexes (Figure 6). Our structure does not
impose any spatial constraint between the different
MEF2 sites as long as they are well separated so the
intervening sequences could be looped out. In fact, the
MEF2 binding sites could even come from different
chromosomes. In this regard, recent ChIP-on-chip
studies reveal that MEF2 bind a much larger number of
sites in the genome than previously thought, and that most
MEF2-targeted promoters contain multiple MEF2
binding sites that are separated far from each other
(often more than several kilobases) (31). Second, as dis-
cussed above, the TAZ domain can interact with a variety
of other proteins, including different transcription factors.
The fact that MEF2 can bind three distinct sites on TAZ2
opens up the possibility that MEF2 may bind one of the
three sites in a given promoter context, leaving room for
the binding of other transcription factors to the TAZ2
domain. This versatility of p300:MEF2 interaction may
facilitate combinatorial control of transcription regulation
between MEF2 and other transcription factors. Future
studies are needed to further address these questions, for
example, by analyzing the effect of mutations at different
interfaces on the expression of speciﬁc subsets of
MEF2-targeted genes.
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